Article

Pirfenidone improves adipose dysfunction and obesity-driven steatohepatitis via mTORC1 signaling

2026-03-21

Abstract excerpt

Obesity-driven metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are shaped by depot-specific adipose tissue dysfunction, including maladaptive expansion and visceral adipose tissue (VAT) fibrosis. Pirfenidone, an anti-fibrotic agent, improves experimental liver disease. However, its actions on adipose depots and adipose–liver crosstalk rem...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebb78fa2-a9b0-5a50-9b21-72eacf38c340
DOI: 10.64898/2026.03.20.713092

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pirfenidone improves adipose dysfunction and obesity-driven steatohepatitis via mTORC1 signalingDOI 10.64898/2026.03.20.713092Read

Modulation of metabolic, inflammatory, fibrotic and cell death pathways by Resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): A transcriptomic profiling studySemantic proximity Read

<i>Patolakaturohiniyadi Kashayam</i> , exerts anti-steatotic and anti-obesogenic effects via coordinated regulation of lipid metabolism, inflammation, and incretin signallingSemantic proximity Read

Hepatic loss of AATF attenuates MASH by suppressing AKT–mTORC1 signaling and reprogramming lipid metabolismSemantic proximity Read

Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different gradesSemantic proximity Read

SREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic StrategiesSemantic proximity Read

An 8-Week Very Low-Calorie Ketogenic Diet (VLCKD) Alters the Landscape of Obese-Derived Small Extracellular Vesicles (sEVs), Redefining Hepatic Cell Phenotypes.Semantic proximity Read

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read

Orchestration of Gut–Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic InnovationSemantic proximity Read

Cyclodipeptides Reversed Liver Damage and Adipose Tissue Dysfunction in a Chronic Obesity MASLD Rat Model by Remodeling White Adipocytes Toward a Beige-like Adipocyte Phenotype.Semantic proximity Read

Rap1 Activation Protects Against Fatty Liver and Non-Alcoholic Steatohepatitis DevelopmentSemantic proximity Read

Shenling Baizhu San Ameliorates Metabolic-Associated Fatty Liver Disease Complicated with Sarcopenia via Regulating AMPKα SignalingSemantic proximity Read

A Unified Mechanistic Framework for Metabolism-Based Therapeutics in MASH: A Comprehensive Review of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and StatinsSemantic proximity Read